CD40LG and neoplasm: The ability to extrinsically introduce CD40L expression into the tumor by transducing with nonreplicating adenoviral infection has been tested in several small clinical trials and has shown some intriguing clinical improvements in patients with advanced malignancies [80, 94, 97].